Ozempic Plateau: Why You Stopped Losing Weight

Is it normal to stop losing weight on Ozempic?

The scale has not moved in six weeks and nobody has told you whether that is the medication failing or the medication doing exactly what it did in the trials.

It is usually the second one. A plateau is a documented feature of the weight curve, not a sign something went wrong. The published report of the STEP 5 trial states that in the 68-week trials, reductions in weight, waist circumference, blood pressure and HbA1c "appeared to plateau around week 60 with semaglutide." That flattening was expected and it was measured.

But normal and nothing to look at are different claims, and most pages on this question collapse them into one. Four separate things produce a flat scale. They have four different answers, and being told to be patient when you are actually sitting on a starter dose is bad advice dressed as reassurance.

When does weight loss actually flatten in the trials?

Late, and later than most people expect. The curve is steepest in the first several months and shallows through the second half of the first year.

STEP 1 randomised 1,961 adults with obesity, or overweight with at least one weight-related condition and without diabetes, to 68 weeks of once-weekly semaglutide or placebo alongside lifestyle intervention. Mean change in body weight was -14.9% with semaglutide against -2.4% with placebo.

STEP 5 ran the same comparison out to two years in 304 participants. Mean change in body weight from baseline to week 104 was -15.2% with semaglutide against -2.6% with placebo.

Set those side by side and the shape becomes obvious. Roughly another nine months of treatment moved the average by a fraction of a percentage point. These are two different trials with different participants, so this is not a within-person comparison and should not be read as one. It does show the plateau holding rather than reversing while treatment continued.

SURMOUNT-1 tested tirzepatide in 2,539 participants over 72 weeks. On the efficacy estimand, mean weight reductions across its three dose groups were 16.0%, 21.4% and 22.5%, against 2.4% for placebo. On the more conservative treatment-regimen estimand the same groups came in at 15.0%, 19.5% and 20.9%, against 3.1%. Higher ceiling than the semaglutide trials, same basic curve shape.

If you are four months in and flat, you are nowhere near where these curves flatten. That is the single most useful thing on this page, and it points at the first cause.

Cause 1: are you actually at a therapeutic dose yet?

This is the cause most often misread as a plateau, and it is not a plateau at all. It is a stall partway up the ramp.

Both trial programs escalated the dose gradually before anyone reached the level being studied. The STEP 5 report describes a fixed escalation schedule stepping up every four weeks, with participants reaching the trial's maintenance dose at week 16. STEP 1 is described the same way, as 68 weeks of treatment including 16 weeks of dose escalation. So the headline results everyone quotes were produced by people who spent their first four months climbing.

A flat month while you are still below the maintenance dose used in the trial is a different situation from a flat month at the top of the ramp. The first may resolve as escalation continues. The second is the real plateau discussed below. We are not going to tell you what dose you should be on or when to move: your schedule belongs to your prescriber and the product label. What we will say is that "where am I relative to the trial maintenance dose, and what is the plan from here" is a specific, answerable question worth walking into your next appointment with.

The difference is structural and checkable. Embody advertises flat monthly pricing for both its semaglutide and tirzepatide programs, with no step up as the dose rises, verified on their live pricing page on 2026-07-31. Maximus, by contrast, states that after its introductory period, pricing moves to standard rates that scale with your dose level. Neither is wrong to price the way it does, and flat is not automatically cheaper once consultation and lab fees are counted. But if your program will not escalate you, or charges more every time it does, that is a concrete reason to compare what other programs commit to or check the price index across all 53 programs we track.

Cause 2: the expected plateau, the one the trials describe

If you are past the escalation period and well into your first year, this is the likeliest answer, and it is the least satisfying one.

Weight loss on these medications is not linear and was never going to be. The published plateau in the 68-week trials sat around week 60. STEP 5's week-104 mean of -15.2% shows the flattening persisting through a second year of continued treatment rather than reversing into regain.

Here is the part the reassuring version leaves out. If you started expecting the trial average and arrived at it, the plateau is the trial working. If you started expecting the SURMOUNT-1 upper figures and landed near the STEP 1 average, being told "this is the expected plateau" is disappointing news, and it deserves to be delivered as news rather than encouragement. Trial means are averages, and individual results spread widely either side of them.

Cause 3: is your body burning less than it used to?

Some of the plateau is arithmetic. A smaller body costs less to run, so the deficit that produced the first phase of loss shrinks on its own even if nothing about your eating changed.

On top of that arithmetic sits metabolic adaptation, sometimes called adaptive thermogenesis: resting energy expenditure falling by more than the loss of tissue alone would predict. A review of energy expenditure changes with weight gain and loss reports that measured adaptive thermogenesis varied between roughly 100 and 500 kcal per day across studies, and that it explained about 50% of the less-than-expected weight loss in patients with obesity. Those are ranges across different study designs and populations, not a number that applies cleanly to you.

This cause is real, it is measurable in research settings, and it is largely not something you can undo by trying harder. What it changes is the interpretation: a plateau here is your body defending a lower weight, which is a different problem from a dose problem and does not respond to the same fix.

Cause 4: has your intake crept back up as side effects faded?

The fourth cause is the one people are least willing to consider about themselves, and the one with the thinnest published evidence.

The mechanism is straightforward. Nausea, early fullness and food aversion are most pronounced during the escalation phase, which is why the side effect curve and the weight curve tend to flatten at the same time. As tolerance builds, those effects commonly soften. The appetite suppression that made eating less feel effortless in month two can feel considerably less dramatic by month eight, and portions can drift upward without any deliberate decision to eat more.

We have to be straight about the evidence: we could not source a trial that isolated changes in caloric intake over time within a treated group and tied it specifically to the plateau. Treat this as a mechanism that is plausible and widely described clinically, not one with a trial number behind it. The practical consequence is that it is the only one of the four causes you can test yourself, by recording intake honestly for a fortnight and comparing it to your early months.

Does muscle loss cause the plateau?

Muscle belongs in this conversation, but not usually as the answer to it.

An exploratory body composition analysis within STEP 1, using DEXA in a subgroup of 140 participants, found that with semaglutide, total fat mass fell 19.3% from baseline and regional visceral fat mass fell 27.4%. Total lean body mass also fell, by 9.7%. At the same time, lean mass as a proportion of total body mass rose by 3.0 percentage points.

Both halves are true and people quote whichever suits them. Lean tissue was genuinely lost in absolute terms, and body composition still improved on the ratio measure, because fat was lost faster than lean tissue was.

Whether losing less lean mass would have delayed or prevented the plateau is a question that analysis did not ask and cannot answer. Muscle is metabolically active, so a link to the energy expenditure story in cause three is plausible. Plausible is not tested. Anyone telling you confidently that protecting muscle will break your plateau is going beyond what these trials measured.

What actually changes a plateau, and what does not?

Sort your options by which cause they address. Anything that addresses a cause you do not have will do nothing, which is why generic plateau advice has such a poor hit rate.

One more data point worth holding onto, because it reframes what a plateau even is. In the STEP 1 trial extension, participants who came off semaglutide regained 11.6 percentage points of their lost weight over the following year, ending at a net loss of 5.6% from baseline against 17.3% while on treatment. The authors concluded that the findings "confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health."

A plateau is not the medication ceasing to do anything. Holding a lower weight is itself the medication working against a regain pressure the extension study made visible.

When does a plateau mean the medication is not working for you?

There is a version of this where the honest answer is that this drug, at a dose you can tolerate, is not producing a clinically meaningful result for you. That version exists and it is not a personal failure.

The signals: you have been at the maintenance dose your prescriber intends for a sustained period rather than still climbing, your intake has genuinely not drifted, and the total change from baseline remains far below what the trial populations averaged. That combination is a different conversation from a plateau at month five.

We are deliberately not putting a percentage-at-a-given-week threshold on that, because we could not source one from the trial records or labelling that we would be willing to hand you as a rule. Clinical practice does use response thresholds to decide whether to continue, adjust or switch. Ask what threshold your prescriber uses rather than adopting one from an article. If switching molecules comes up, semaglutide versus tirzepatide covers what the trials actually compared.

Three things to bring to that appointment, which will make it a shorter and more productive conversation than turning up with "it stopped working":

• •A dated weight log, ideally weekly and taken under the same conditions, going back to your start date. The shape of your own curve is the evidence. A single stalled number is not.
• •The date you reached your current dose, and whether further escalation is planned. This separates cause one from causes two through four in about thirty seconds.
• •An honest two-week record of what you are eating now, next to your best recollection of your first two months. This is the only cause you can bring your own data on.

Frequently Asked Questions

How long does an Ozempic plateau last?

It depends on which cause you have, which is why no single number answers this. In the trials, the flattening that began around week 60 persisted rather than resolving: STEP 5 measured a mean change of -15.2% at week 104, close to what STEP 1 measured at week 68. A plateau that is escalation-related may instead resolve as titration continues. Your prescriber is the one who can tell which of those you are in.

Is a plateau at three or four months normal?

A flat stretch that early sits well before the point where the trial curves flatten, and it overlaps with the period when many people are still moving up through their titration schedule. STEP 1 is described as 68 weeks of treatment including 16 weeks of dose escalation, so trial participants spent roughly their first four months climbing before reaching the maintenance dose. A stall in that window is worth raising with your prescriber rather than waiting out.

Does the plateau mean I should switch from semaglutide to tirzepatide?

That is a prescribing decision, and it depends on your history, tolerability and coverage. What the published data supports saying is that the tirzepatide trial reached higher mean reductions: SURMOUNT-1 reported 16.0% to 22.5% across three dose groups at 72 weeks on the efficacy estimand, against -14.9% at 68 weeks in STEP 1. Those are separate trials with different designs and populations, so the comparison is indicative rather than head to head.

Will I regain the weight if I stop because I plateaued?

The STEP 1 extension is the direct evidence. One year after semaglutide was withdrawn, participants had regained 11.6 percentage points of their lost weight, leaving a net loss of 5.6% from baseline compared with 17.3% at the end of treatment. The authors concluded that ongoing treatment is required to maintain the improvements. Stopping is a decision to make with your prescriber, not one to make because the scale went quiet.

Should I eat less to break through a plateau?

Only if intake drift is genuinely your cause, and cutting further carries a real cost against the lean mass picture above. If the plateau is driven by metabolic adaptation or by having reached the trial ceiling, eating less is unlikely to restart the curve and may make adherence harder. Establish your cause first.

Sources